Viking Therapeutics, Inc (VKTX) Dividend History

Company News

• Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity

  Viking Therapeutics is developing VK2735, an oral GLP-1/GIP receptor agonist for obesity treatment with unprecedented tolerability. Early phase 2 results show 14.7% weight loss and a unique 13% discontinuation rate matching placebo, potentially revolutionizing obesity drug market.

  The Motley Fool

  Featured Companies: AMGN LLY PFE
• Viking Therapeutics to Participate at Upcoming Investor Conferences

  Viking Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in upcoming investor conferences, where the company will present its pipeline and hold one-on-one meetings.

  Benzinga
• Viking Therapeutics EPS Miss Overlooked as Long-Term Pipeline Gains Focus

  Viking Therapeutics reported a Q1 earnings miss, but investors are focusing on the company's long-term pipeline, particularly its promising GLP-1 candidate VK2735 which showed faster weight loss than current obesity drugs.

  Investing.com

  Featured Companies: LLY
• Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings? - Zacks Investment Research

  Viking Therapeutics, a biotech firm without any marketed drugs, is set to report its Q2 earnings. Investors will focus on updates related to its pipeline candidates, including VK2809 for NASH and VK2735 for obesity. The company's strong cash balance and robust pipeline development provide growth potential, though it faces competition in the obesity market.

  Zacks Investment Research

  Featured Companies: LLY MDGL